Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top winning strategies
3.2.2. Top investment pockets

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis

CHAPTER 4 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PIRFENIDONE

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NINTEDANIB

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe

5.4. ASIA-PACFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. South Korea
5.4.8. Rest of Asia-Pacific

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA

CHAPTER 6 COMPANY PROFILES

6.1. MEDICINOVA, INC.

6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments

6.2. BOEHRINGER INGELHEIM

6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments

6.3. F. HOFFMANN-LA ROCHE

6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves and developments

6.4. FIBROGEN, INC.

6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments

6.5. PROMEDIOR, INC.

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments

6.6. MERCK & CO., INC.

6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments

6.7. GALAPAGOS NV

6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments

6.8. BIOGEN

6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments

6.9. BRISTOL-MYERS SQUIBB COMPANY

6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments

6.10. PROMETIC LIFE SCIENCES INC.

6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments

6.11. CIPLA INC.

6.11.1. Company overview
6.11.2. Operating business segments
6.11.3. Business performance
6.11.4. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 2. PIRFENIDONE MARKET, BY REGION, 2016-2023, ($MILLION)
TABLE 3. PIRFENIDONE MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 4. NINTEDANIB MARKET, BY REGION, 2016-2023, ($MILLION)
TABLE 5. NINTEDANIB MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 6. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION, 2016-2023, ($MILLION)
TABLE 7. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 8. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 9. U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 10. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 11. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 12. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 13. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 14. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 15. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 16. UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 17. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 18. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 19. REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 20. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 21. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 22. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 23. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 24. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 25. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 26. REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 27. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 28. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE, 2016-2023, ($MILLION)
TABLE 29. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 30. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 31. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 32. REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 33. MEDICINOVA, INC.: COMPANY SNAPSHOT
TABLE 34. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 35. ROCHE: COMPANY SNAPSHOT
TABLE 36. FIBROGEN: COMPANY SNAPSHOT
TABLE 37. PROMEDIOR: COMPANY SNAPSHOT
TABLE 38. MERCK: COMPANY SNAPSHOT
TABLE 39. GALAPAGOS: COMPANY SNAPSHOT
TABLE 40. BIOGEN: COMPANY SNAPSHOT
TABLE 41. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 42. PROMETIC LIFE SCIENCES INC.: COMPANY SNAPSHOT
TABLE 43. CIPLA INC.: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION
FIGURE 2. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (20142016)
FIGURE 3. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 5. TOP INVESTMENT POCKETS
FIGURE 6. MARKET SHARE ANALYSIS, 2016
FIGURE 7. IMPACT ANALYSIS, 2016

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.